Truist Securities upgrades Edwards Lifesciences to Buy from Hold, raises price target to $113 from $95

Edwards Lifesciences (NYSE: EW) reported Q3 2026 sales of $1.72 billion, up 11.2%, and raised its 2026 sales growth outlook to ~11.5% and adjusted EPS to $2.97-$3.05, citing strong momentum in TAVR and TMTT.

Edwards Lifesciences reported Q3 Non-GAAP EPS of $0.80, exceeding estimates by $0.06, with revenue of $1.72B, up 11.0% Y/Y and $40M above expectations. The company raised its full-year sales growth guidance to approximately 11.5% from 10-11%.

Edwards Lifesciences Corp (EW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · www.edwards.com FOR IMMEDIATE RELEASE Media: Eric Endicott, media@edwards.com Investors: Gerianne Sarte, investor_relations@edwards.com EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESUL

Edwards Lifesciences reported Q3 sales growth of 11.2% and adjusted EPS of $0.80. The company raised its 2026 sales growth guidance to 11.5% from 10-11% and TAVR growth guidance to 9-9.5% from 8-9%.

Edwards Lifesciences reported Q3 2023 sales growth of 10.5% to $1.72B, with TAVR sales up 8.0% to $1.24B and TMTT sales up 44.0% to $207M. EPS was $0.53, up 19% YoY. The company raised its 2023 guidance, including total sales growth to ~11.5% and adjusted EPS to $3.05. Recent highlights include FDA approvals for PASCAL Precision and AUTUS, and positive clinical trial results presented at TCT 2023.

Edwards Lifesciences (EW) reported positive results from its CLASP II TR trial, showing that the PASCAL system improved outcomes in tricuspid regurgitation patients. After one year, 80% of patients treated with the PASCAL system achieved moderate or less severe tricuspid regurgitation, compared with 30% in the control group. The company plans to announce Q3 2026 results on November 4, 2026, and EW stock closed at $93.26, up 1.36%.